Video

Dr Jeff Patton Reflects on OCM Performance Period 4 Results, Taking on 2-Sided Risk

Jeff Patton, MD, chief executive officer of Tennessee Oncology, weighs in on Oncology Care Model (OCM) performance period 4 results and taking on 2-sided risk.

Jeff Patton, MD, chief executive officer of Tennessee Oncology, weighs in on Oncology Care Model (OCM) performance period 4 results and taking on 2-sided risk.

Transcript

With OCM performance period 4 results now out, how did the results compare with the last 2 performance periods?

So, very similar. Every period we’ve generated savings against the target but every period we’ve not gotten a performance payment. The good news is as it applies to 2-sided risk, that means we would not have had any recruitment, so I think most likely we’re going to go and do 2-sided risk.

What are your thoughts on taking on 2-sided risk?

Risk is risk, so it makes everybody nervous, but with 4 consecutive performance periods where we’re in what we call the safe zone, we have a comfort level. We are investigating stop loss or reinsurance and I’ll have a lot more confidence if I have an insured downside.

Related Videos
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Hans Lee, MD
Screenshot of an interview with Amir Ali, PharmD, BCOP
Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey
 Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center
Divya Gupta, MD
Dr Cesar Davila-Chapa
Matias Sanchez, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo